Immuneering
Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors — a proprietary class of MEK inhibitors — with lead drug atebimetinib in pivotal Phase 3 for first-line pancreatic cancer and Phase 2 for RAS-mutant NSCLC, targeting cancer patients with limited treatment options.
- Company typePublic
- Founded2008
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immuneering does
Immuneering Corporation is a Cambridge, Massachusetts-based clinical-stage oncology company developing Deep Cyclic Inhibitors, a proprietary class of MEK inhibitors designed to disrupt tumor adaptation through rhythmic dosing that delivers strong MEK inhibition followed by a short recovery window, repeating daily. The lead candidate atebimetinib (IMM-1-104) is an oral, once-daily Deep Cyclic Inhibitor in pivotal Phase 3 development (MAPKeeper 301) for first-line metastatic pancreatic cancer in combination with modified gemcitabine/nab-paclitaxel, and in Phase 2 development for RAS-mutant non-small cell lung cancer in combination with Regeneron's Libtayo and Eli Lilly's olomorasib. A second Deep Cyclic Inhibitor, envometinib (IMM-6-415), completed Phase 1/2a in April 2025 and is positioned as a Phase 2-ready partnering asset. Phase 2a data showed a 17.3-month median overall survival in 55 first-line pancreatic cancer patients versus an 8.5-month historical benchmark, with ctDNA analysis from 123 patients demonstrating rare acquired resistance mutations.
The company is pre-revenue and reports no product sales; it monetizes only through future drug commercialization or potential partnering transactions. As of Q1 2026, Immuneering held approximately $198.6 million in cash, cash equivalents, and marketable securities with runway into 2029, following a ~$225 million September 2025 public offering and a $25 million August 2025 private placement led by Sanofi. With 51–100 employees, FDA and EMA Phase 3 alignment secured, Nasdaq Biotechnology Index inclusion (December 2025), and a market capitalization of approximately $309–359 million, the company is positioning for its first pivotal readout (topline mid-2028) and eventual commercial launch in pancreatic cancer. The business model is the standard clinical-stage biotech path: build clinical evidence through Phase 2/3 trials, establish credibility via ASCO/AACR presentations and peer-reviewed publications, secure KOL engagement, and pursue either direct specialty-pharmacy commercialization or co-development/co-commercialization partnerships with large pharma counterparties such as Sanofi, Regeneron, and Eli Lilly.
Immuneering firmographics
Firmographics- Name
- Immuneering
- Legal name
- Immuneering Corporation
- Website
- https://immuneering.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors — a proprietary class of MEK inhibitors — with lead drug atebimetinib in pivotal Phase 3 for first-line pancreatic cancer and Phase 2 for RAS-mutant NSCLC, targeting cancer patients with limited treatment options.
- Ownership category
- akta.pro rank
Immuneering industry classification
Industry- Product category
- Clinical-stage Oncology Therapeutics
- NAICS
- Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), NK Cell Therapies (HLAAABAD)
Keywords
Where Immuneering is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Immuneering business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. The company is developing oncology drugs (atebimetinib, envometinib) targeting MAPK-driven cancers. No commercial products yet; all candidates are in clinical trials. Future revenue will come from drug sales upon regulatory approval.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Immuneering product offering
Product offeringCore offering
Immuneering develops Deep Cyclic Inhibitors, a proprietary class of MEK inhibitors that deliver pulsed drug exposure to outpace tumor adaptive resistance. Its lead clinical asset atebimetinib (IMM-1-104) is being evaluated in the global Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer and in Phase 2 for RAS-mutant non-small cell lung cancer, while envometinib (IMM-6-415) is a Phase 2-ready second asset.
Product overview
Immuneering is a clinical-stage oncology company developing Deep Cyclic Inhibitors, a novel class of targeted cancer therapies. The company's lead product is atebimetinib (IMM-1-104), an oral, once-daily MEK inhibitor that uses rhythmic pulsing to disrupt tumor adaptation while allowing healthy cells to recover. Atebimetinib is in Phase 3 development (MAPKeeper 301) for first-line pancreatic cancer and Phase 2 for lung cancer. The second product, envometinib (IMM-6-415), is a twice-daily Deep Cyclic Inhibitor that completed Phase 1 in 2025 and is available for partnering.
Differentiator
Problem solved
Functional benefit
Brands
- Deep Cyclic Inhibitors: A new class of targeted therapies designed to minimize cumulative toxicities, disrupt cancer's rapid adaptive behaviors, and reduce resistance while enabling longer-lasting therapeutic benefit.
Products and services
- Atebimetinib (IMM-1-104) Oral, once-daily Deep Cyclic Inhibitor of MEK in late-stage clinical trials for first-line pancreatic cancer and non-small cell lung cancer. Designed to target RAS, RAF, and MAPK pathway-driven cancers with greater durability and tolerability through a rhythmic pulsing approach.
- Envometinib (IMM-6-415) Oral, twice-daily Deep Cyclic Inhibitor of MEK. Phase 1/2a trial completed in April 2025 in patients with advanced or metastatic solid tumors harboring RAS or RAF oncogenic mutations. Phase 2-ready asset available for partnering.
- MAPKeeper 301 Phase 3 Trial Global pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic adenocarcinoma. Expected enrollment of approximately 510 patients with topline results expected mid-2028.
Quantifiable outcome
- 64% overall survival at 12 months (vs 35% historical benchmark) in first-line pancreatic cancer patients treated with atebimetinib plus mGnP
- +5 more outcomes
Companies that use Immuneering
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Immuneering technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Immuneering partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and supporting.
- Regeneron PharmaceuticalscoreImmuneering and Regeneron established a clinical supply agreement to evaluate atebimetinib (IMM-1-104) in combination with Libtayo (cemiplimab), Regeneron's FDA-approved PD-1 checkpoint inhibitor, with or without chemotherapy, in patients with first-line metastatic RAS-mutant non-small cell lung cancer. First patient dosing expected in 2H 2026.
- Eli Lilly and CompanycoreImmuneering and Lilly established a clinical supply agreement to evaluate atebimetinib (IMM-1-104) in combination with olomorasib (Lilly's KRAS G12C inhibitor) in patients with KRAS G12C-mutant non-small cell lung cancer.
- PanCAN (Pancreatic Cancer Action Network)supportingImmuneering supports PanCAN as a Scientific & Medical Industry Champion, aligning with the company's goal to help people with pancreatic cancer live longer and feel better through participation in patient advocacy and awareness initiatives.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Immuneering competitors and assessment
Company assessmentDirect peers
- Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors targeting RAS-driven cancers, including pancreatic cancer and NSCLC. Most directly comparable peer given shared focus on inhibiting the MAPK pathway in RAS-mutant tumors with novel mechanism approaches.
- Erasca: Precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, including pan-RAS and pan-RAF inhibitors. Closely aligned in mission and target biology with Immuneering's MEK Deep Cyclic Inhibition approach.
- Mirati Therapeutics: Developed Krazati (adagrasib), a KRAS G12C inhibitor approved for NSCLC, and was acquired by Bristol-Myers Squibb in 2024 for ~$4.8B. Directly comparable as a RAS-targeted oncology company in the same therapeutic space as Immuneering.
- Relay Therapeutics: Clinical-stage precision oncology company developing small molecule therapies targeting driver mutations in cancer, including RAS-driven tumors. Comparable as a small-molecule precision oncology peer with similar development-stage profile.
- Black Diamond Therapeutics: Precision oncology company developing small molecule kinase inhibitors against allosteric and oncogenic driver mutations, including in the MAPK pathway. Comparable in scale, stage, and approach to Immuneering.
Emerging players
- Day One Biopharmaceuticals: Clinical and commercial-stage oncology company developing targeted therapies for genomically defined cancers, including pediatric and adult tumors. Comparable as a small-molecule targeted oncology peer with a focus on rare/genomically defined indications.
- Foghorn Therapeutics: Clinical-stage biotechnology company developing medicines targeting the chromatin regulatory system in cancer. Comparable as a precision oncology platform company of similar size and stage, with oncology focus but distinct mechanism.
- Cogent Biosciences: Clinical-stage biotechnology company developing precision therapies for genetically defined diseases, including oncology. Comparable as a small-cap precision oncology peer of similar size and clinical stage.
- Zentalis Pharmaceuticals: Clinical-stage small molecule oncology company developing a pipeline of targeted cancer therapies. Notable comparable because Diana Hausman, an Immuneering board member, was formerly CMO at Zentalis, indicating direct familiarity with the company's profile.
Others
- Array BioPharma: Acquired by Pfizer in 2019 for ~$11.4B; developed Mekinist (trametinib) and Braftovi (encorafenib), approved MEK and BRAF inhibitors widely used in melanoma and other MAPK-driven cancers. Relevant precedent for what a successful MEK inhibitor franchise can look like at scale.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Immuneering social profiles
Digital presenceImmuneering financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immuneering leadership team
Management profileNumber of profiles
Profiles17 records
Immuneering funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immuneering M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immuneering
What does Immuneering do?
Immuneering develops Deep Cyclic Inhibitors, a proprietary class of MEK inhibitors that deliver pulsed drug exposure to outpace tumor adaptive resistance. Its lead clinical asset atebimetinib (IMM-1-104) is being evaluated in the global Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer and in Phase 2 for RAS-mutant non-small cell lung cancer, while envometinib (IMM-6-415) is a Phase 2-ready second asset.
Is Immuneering a public or private company?
Immuneering is a public company. It is classified as public and is currently operating.
When was Immuneering founded?
Immuneering was founded in 2008. It employs 51 to 100 people.
Where is Immuneering based?
Immuneering is headquartered in Cambridge, United States, in the North America region.
How does Immuneering make money?
One revenue line is on record: drug Development and Commercialization.
Who are Immuneering's main competitors?
Direct peers on record are Revolution Medicines, Erasca, Mirati Therapeutics, Relay Therapeutics and Black Diamond Therapeutics. Emerging players are Day One Biopharmaceuticals, Foghorn Therapeutics, Cogent Biosciences and Zentalis Pharmaceuticals. Array BioPharma is listed as an others.
Does Immuneering have an API?
No public API is recorded for Immuneering.
What industry is Immuneering in?
Immuneering's product category is Clinical-stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 5417 and its SIC code is 2835.